Skip to content
10-K

Annual Report

Titan Pharmaceuticals, Inc.

0001829126-25-001934

← back to feed
Filed
Mar 20, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 12, 2025 914.23K sh
Shares Diluted FY 2024 · Dec 31, 2024 899K sh
Shares Diluted FY 2024 · Dec 31, 2023 752K sh
Operating Cash Flow FY 2024 · Dec 31, 2024 −$3.88M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$7.09M
Cash And Equivalents FY 2024 · Dec 31, 2024 $2.83M
Cash And Equivalents FY 2024 · Dec 31, 2023 $6.76M
Stockholders Equity FY 2024 · Dec 31, 2024 $2.44M
Stockholders Equity FY 2024 · Dec 31, 2023 $6.64M
Stockholders Equity FY 2024 · Dec 31, 2022 $1.36M
Current Liabilities FY 2024 · Dec 31, 2024 $483K
Current Liabilities FY 2024 · Dec 31, 2023 $1.44M
Total Liabilities FY 2024 · Dec 31, 2024 $483K
Total Liabilities FY 2024 · Dec 31, 2023 $1.44M
Current Assets FY 2024 · Dec 31, 2024 $2.92M
Current Assets FY 2024 · Dec 31, 2023 $8.02M
Total Assets FY 2024 · Dec 31, 2024 $2.92M
Total Assets FY 2024 · Dec 31, 2023 $8.09M
Eps Diluted FY 2024 · Dec 31, 2024 −$5.23
Eps Diluted FY 2024 · Dec 31, 2023 −$7.41
Eps Basic FY 2024 · Dec 31, 2024 −$5.23
Eps Basic FY 2024 · Dec 31, 2023 −$7.41
Net Income FY 2024 · Dec 31, 2024 −$4.71M
Net Income FY 2024 · Dec 31, 2023 −$5.57M
Operating Income FY 2024 · Dec 31, 2024 −$4.56M
Operating Income FY 2024 · Dec 31, 2023 −$7.28M
Capex FY 2024 · Dec 31, 2023 $2K
Rd Expense FY 2024 · Dec 31, 2023 $1.91M